CellMax Life is using the grant to increase automation and commercialization efforts for its early cancer circulating tumor cell detection platform CellMax CMx.
Here’s what you should know:
1. The company is using its device initially to detect colorectal cancer.
2. The company wants to increase CRC screening compliance for high-risk populations and for people over 50 years old.
3. In high-risk patients, a clinical study showed the CMx Platform correctly identified patients with colorectal cancer 90 percent of the time.
4. President and CEO of CellMax Life Atul Sharan said in a release, “This is additional recognition that our CTC Technology is enabling early cancer detection in the high-growth cancer diagnostics area.”
More articles on gastroenterology:
Boston Scientific continues to pour money into endoscopy — Why?
GI leader to know: Dr. Cynthia Wait of Illinois Gastroenterology Group
XBiotech discontinues its phase III trial & more — 6 GI company key notes
